Company intelligence / Profile preview

UC-Care

Israelucnet.universityofcalifornia.edu ↗

Ownership: Private
Development stage: Other

Overview

UC-Care has developed FDA-approved medical devices that improve the accuracy of prostate biopsies by fusing MRI and ultrasound imaging in real time. Their Navigo system enhances detection rates for prostate cancer, while the SmartBx system digitizes biopsy specimens to increase localization accuracy. Clinical data indicate a 25% increase in cancer detection/localization with their technology.

Therapeutic areas: Men's HealthOncology
Modalities: Device
Industry: Medical Imaging

Beyond the preview

Go deeper on UC-Care.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on UC-Care.

Explore the full profile